0001654954-18-004222.txt : 20180423 0001654954-18-004222.hdr.sgml : 20180423 20180423060412 ACCESSION NUMBER: 0001654954-18-004222 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180423 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20180423 DATE AS OF CHANGE: 20180423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MYMETICS CORP CENTRAL INDEX KEY: 0000927761 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 251741849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25132 FILM NUMBER: 18767846 BUSINESS ADDRESS: STREET 1: EUROPEAN EXECUTIVE OFFICE STREET 2: 4, ROUTE DE LA CORNICHE CITY: EPALINGES STATE: V8 ZIP: CH-1066 BUSINESS PHONE: 011-41-21-653-45-35 MAIL ADDRESS: STREET 1: EUROPEAN EXECUTIVE OFFICE STREET 2: 4, ROUTE DE LA CORNICHE CITY: EPALINGES STATE: V8 ZIP: CH-1066 FORMER COMPANY: FORMER CONFORMED NAME: ICHOR CORP DATE OF NAME CHANGE: 19970407 FORMER COMPANY: FORMER CONFORMED NAME: PDG REMEDIATION INC DATE OF NAME CHANGE: 19940801 8-K 1 mymx_8k.htm CURRENT REPORT Blueprint
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): April 23, 2018 (April 16, 2018)
 
Mymetics Corporation
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-25132
 
25-1741849
(State of other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
Route de la Corniche 4
1066 Epalinges, Switzerland
 
NA
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: +011 41 21 653 45 35
 
 
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
Item 8.01    Other Events.
 
The registrant, Mymetics Corporation (“Mymetics”), entered into a Research and Option to License Agreement (the “Research Agreement”) dated April 16, 2018, with Anergis SA (“Anergis”). Under the terms of the Research Agreement, a pre-clinical study program will evaluate the immunogenicity profile of the Anergis’ peptides designed to treat birch allergy when presented on Mymetics’ proprietary virosomes, with or without undisclosed TLR ligands or other adjuvants, and will compare the results to Anergis’ AllerT product combination. The results of the program are expected in the first quarter of 2019.
 
In the event that the results of the pre-clinical study program are successful, Anergis has the option to obtain an exclusive worldwide license of Mymetics’ virosome technology for the development of allergy vaccines. Should Anergis and Mymetics execute a License and Collaboration Agreement (LCA), Anergis would make an upfront payment to Mymetics in an amount that increases as the date of executing the LCA is delayed, milestone payments based on certain regulatory clearances and royalties for net sales.
 
Mymetics has issued a press release summarizing the terms of the Research Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1.
 
Item 9.01.    Financial Statements and Exhibits
 
 (d) Exhibits.
 
99.1    Press Release dated April 23, 2018
 
 
2
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
MYMETICS CORPORATION
 
 
 
 
 
Date: April 23, 2018
By:  
/s/ Ronald Kempers
 
 
 
Ronald Kempers
 
 
 
President and Chief Executive Officer
 
 
 
 
 
 
 
3
EX-99.1 2 mymx_ex991.htm PRESS RELEASE Blueprint
 
 Exhibit 99.1
 
Press Release
 
Anergis and Mymetics Start Research Collaboration Project on the use of Virosomes for Ultra-Fast Allergy Immunotherapy
 
Epalinges, Switzerland, April 23, 2018 – Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines, and Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, announced today that Mymetics SA, the Swiss subsidiary of Mymetics Corporation and Anergis SA have entered into a Research Collaboration project.
 
The pre-clinical study program will evaluate the immunogenicity profile of the Anergis peptides designed to treat birch allergy (the Bet v1 COPs) when presented on Mymetics’ proprietary virosomes, with or without undisclosed TLR ligands or other adjuvants, and will compare the results to Anergis’ AllerT product combination (Bet v1 COPs with aluminum hydroxide).
 
The research collaboration will start now and the results are expected by Q1 2019. If this project is successful, Anergis will have the option to enter into an exclusive license agreement for the use of virosomes in allergy.
 
“We are very excited to start this initial research project with Anergis, a leading company in ultra-fast allergy immunotherapy” said Ronald Kempers, CEO of Mymetics. “We look forward to show that our proprietary virosome technology and vaccine expertise can make a valuable difference in improving the effectiveness of treating allergies.”
 
“On the basis of the extensive clinical experience available with virosomes and with Anergis COPs against birch allergy, we are convinced that their combination represents a highly attractive opportunity to develop safe and efficacious ultra-fast COP allergy vaccines” commented Vincent Charlon, CEO of Anergis.
 
About Mymetics
Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has five vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Chikungunya, Herpes Simplex Virus and the RSV vaccine. HIV, malaria and intra-nasal influenza vaccines have successfully finished Phase 1 clinical trials, while the others are in the pre-clinical phase.
 
Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Mymetics’ vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, in combination with humoral and cellular immune responses as a second-line defense, which can be essential for the development of an effective vaccine.
 
For further information, please visit www.mymetics.com.
 
About Anergis
Anergis SA is a Swiss biopharmaceutical company dedicated to the discovery and development of novel, ultra-fast, proprietary allergy immunotherapy products for the most prevalent allergies. Anergis core technology is based on Contiguous Overlapping Peptides (COP) which together contain the full amino acid sequence of one or more major allergens ; COP do not bind the pre-existing IgE of allergic patients and can therefore be administered at higher doses than allergens without the risk of immediate allergic reactions. Anergis completed three clinical Phase II trials with its product candidate against birch pollen allergies, AllerT, containing Bet v1 COPs and aluminium hydroxide as an adjuvant. Two additional COP product candidates against ragweed pollen (Amb a1 COPs) and house dust mite (Der p COPs) allergies are in preclinical development. Anergis has raised over CHF 52 million from private and institutional investors, including BioMedInvest, Renaissance PME, Sunstone Capital, and WJFS, Inc.
 
 
1
 
 
About Allergies
Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world, affecting over 500 million people. The only curative therapy of allergies available today, known as “desensitization”, “allergy shots” or “Conventional Allergy Immunotherapy” (AIT), is the process of inducing tolerance to the allergen by administering the allergen itself to patients. AIT requires three to five years of treatment and exposes patients to the risk of serious side effects such as immediate anaphylactic reactions. With its technology, Anergis is shaping the future of allergy treatment by developing therapeutic modalities that only require two months of treatment.
 
CONTACTS:
Mymetics Corporation
Ronald Kempers
Chief Executive Officer
Tel: +41 21 653 4535
info@mymetics.com
 
Anergis SA
Vincent Charlon
Chief Executive Officer
info@anergis.ch
 
Forward looking statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.
 

 
2